TGFB1 and neoplasm: The results demonstrated that anti-PD-1 monotherapy skewed the CD4+ Treg:CD4+ Th ratio and promoted tumor cell pSmad3 expression, which was reversed upon treatment with α-TGF-β antibodies37.